Held by 2 specialist biotech funds
**Signal Note: Eventide Initiates $48.3M STERIS Position** Eventide's new $48.3M stake in STERIS reflects conviction in the contract sterilization and biotech outsourcing operator ahead of expected margin expansion from capacity utilization and pricing power in its high-margin Sterile Processing Services segment. The position aligns with Eventide's biotech thesis, as STERIS is a critical infrastructure provider to pharma/medtech manufacturers with recurring revenue exposure to the pipeline maturation cycle. No immediate clinical catalyst; this appears to be a capital allocation signal on operational/financial trajectory rather than a near-term product milestone.